CLOs on the Move

Chart SeQual Technologies Inc

www.sequal.com

 
SeQual is committed to a program of continual improvement and expansion of its air separation product line. We constantly strive to identify new opportunities for on-site gas separation that will benefit our customers by improving or cost-reducing their
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Medstreaming

Headquartered in Redmond, WA, Medstreaming is a leading provider of Healthcare IT (“HCIT”) solutions for image intensive specialties. We are focused on enabling proactive patient care and increasing the efficiency of healthcare by providing medical IT solutions to individual practitioners and large institutions alike. Since its founding in 2006, Medstreaming has become a market leader in delivering specialty-based workflow applications that function as a “best of breed” specialties, including, but not limited to, Cardiology, Vascular, Vein & Surgery. Lead by a team of founding engineers, clinical specialists, and healthcare IT veterans, Medstreaming is committed to dramatically improving the delivery of healthcare and disease management, while becoming a global leader developing medical informatics solutions.

GI Dynamics Inc

GI Dynamics Inc is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mainstay Medical

Mainstay is a medical device company focused on commercializing an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP).

BIO-Medical Instruments

BIO-Medical Instruments is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.